BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 17133345)

  • 1. Differential signal transduction of alternatively spliced FGFR2 variants expressed in human mammary epithelial cells.
    Moffa AB; Ethier SP
    J Cell Physiol; 2007 Mar; 210(3):720-31. PubMed ID: 17133345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transforming potential of alternatively spliced variants of fibroblast growth factor receptor 2 in human mammary epithelial cells.
    Moffa AB; Tannheimer SL; Ethier SP
    Mol Cancer Res; 2004 Nov; 2(11):643-52. PubMed ID: 15561780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of fibroblast growth factor receptor 2 overexpression in the human breast cancer cell line SUM-52PE.
    Tannheimer SL; Rehemtulla A; Ethier SP
    Breast Cancer Res; 2000; 2(4):311-20. PubMed ID: 11056689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Involvement of fibroblast growth factor receptor 2 isoform switching in mammary oncogenesis.
    Cha JY; Lambert QT; Reuther GW; Der CJ
    Mol Cancer Res; 2008 Mar; 6(3):435-45. PubMed ID: 18337450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aberrant receptor internalization and enhanced FRS2-dependent signaling contribute to the transforming activity of the fibroblast growth factor receptor 2 IIIb C3 isoform.
    Cha JY; Maddileti S; Mitin N; Harden TK; Der CJ
    J Biol Chem; 2009 Mar; 284(10):6227-40. PubMed ID: 19103595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FGFR2 isoforms support epithelial-stromal interactions in thyroid cancer progression.
    Guo M; Liu W; Serra S; Asa SL; Ezzat S
    Cancer Res; 2012 Apr; 72(8):2017-27. PubMed ID: 22345151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The missense mutation W290R in Fgfr2 causes developmental defects from aberrant IIIb and IIIc signaling.
    Mai S; Wei K; Flenniken A; Adamson SL; Rossant J; Aubin JE; Gong SG
    Dev Dyn; 2010 Jun; 239(6):1888-900. PubMed ID: 20503384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The c-Kit/D816V mutation eliminates the differences in signal transduction and biological responses between two isoforms of c-Kit.
    Pedersen M; Rönnstrand L; Sun J
    Cell Signal; 2009 Mar; 21(3):413-8. PubMed ID: 19049823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic silencing through DNA and histone methylation of fibroblast growth factor receptor 2 in neoplastic pituitary cells.
    Zhu X; Lee K; Asa SL; Ezzat S
    Am J Pathol; 2007 May; 170(5):1618-28. PubMed ID: 17456767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival.
    Kunii K; Davis L; Gorenstein J; Hatch H; Yashiro M; Di Bacco A; Elbi C; Lutterbach B
    Cancer Res; 2008 Apr; 68(7):2340-8. PubMed ID: 18381441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The breast cancer susceptibility gene product fibroblast growth factor receptor 2 serves as a scaffold for regulation of NF-κB signaling.
    Wei W; Liu W; Cassol CA; Zheng W; Asa SL; Ezzat S
    Mol Cell Biol; 2012 Nov; 32(22):4662-73. PubMed ID: 22988296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p38MAPK-activated AKT in HER-2 overexpressing human breast cancer cells acts as an EGF-independent survival signal.
    Diehl KM; Grewal N; Ethier SP; Woods-Ignatoski KM
    J Surg Res; 2007 Sep; 142(1):162-9. PubMed ID: 17612563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibroblast growth factor receptor 2 limits and receptor 1 accelerates tumorigenicity of prostate epithelial cells.
    Feng S; Wang F; Matsubara A; Kan M; McKeehan WL
    Cancer Res; 1997 Dec; 57(23):5369-78. PubMed ID: 9393762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin-like growth factor and epidermal growth factor independence in human mammary carcinoma cells with c-erbB-2 gene amplification and progressively elevated levels of tyrosine-phosphorylated p185erbB-2.
    Ram TG; Dilts CA; Dziubinski ML; Pierce LJ; Ethier SP
    Mol Carcinog; 1996 Mar; 15(3):227-38. PubMed ID: 8597535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blocking HER-2/HER-3 function with a dominant negative form of HER-3 in cells stimulated by heregulin and in breast cancer cells with HER-2 gene amplification.
    Ram TG; Schelling ME; Hosick HL
    Cell Growth Differ; 2000 Mar; 11(3):173-83. PubMed ID: 10768865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dexamethasone inhibits basic fibroblast growth factor-stimulated gastric epithelial cell proliferation.
    Luo JC; Lin HY; Lu CL; Wang LY; Chang FY; Lin HC; Huang YC; Ng KM; Chi CW; Lee SD
    Biochem Pharmacol; 2008 Oct; 76(7):841-9. PubMed ID: 18692028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Differential expression profiles of microRNAs between breast cancer cells and mammary epithelial cells].
    Zhang H; Su SB; Zhou QM; Lu YY
    Ai Zheng; 2009 May; 28(5):493-9. PubMed ID: 19624877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphatidylinositol 3-kinase recruitment by p185erbB-2 and erbB-3 is potently induced by neu differentiation factor/heregulin during mitogenesis and is constitutively elevated in growth factor-independent breast carcinoma cells with c-erbB-2 gene amplification.
    Ram TG; Ethier SP
    Cell Growth Differ; 1996 May; 7(5):551-61. PubMed ID: 8732665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of the SNT-1/FRS2 phosphotyrosine binding domain inhibits activation of MAP kinase and PI3-kinase pathways and antiestrogen resistant growth induced by FGF-1 in human breast carcinoma cells.
    Manuvakhova M; Thottassery JV; Hays S; Qu Z; Rentz SS; Westbrook L; Kern FG
    Oncogene; 2006 Sep; 25(44):6003-14. PubMed ID: 16682955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The roles of FGF signaling in germ cell migration in the mouse.
    Takeuchi Y; Molyneaux K; Runyan C; Schaible K; Wylie C
    Development; 2005 Dec; 132(24):5399-409. PubMed ID: 16291796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.